Effectiveness of pneumococcal polysaccharide vaccine in older adults

被引:432
|
作者
Jackson, LA
Neuzil, KM
Yu, OC
Benson, P
Barlow, WE
Adams, AL
Hanson, CA
Mahoney, LD
Shay, DK
Thompson, WW
机构
[1] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[6] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2003年 / 348卷 / 18期
关键词
D O I
10.1056/NEJMoa022678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk of community-acquired pneumonia. In a large population of older adults, we assessed the effectiveness of the pneumococcal vaccine. METHODS: In this retrospective cohort study, 47,365 Group Health Cooperative members 65 years of age or older were assessed over a three-year period. The primary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review), pneumonia in patients who were not hospitalized (``outpatient pneumonia,'' determined from administrative data sources), and pneumococcal bacteremia. The association between pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazards models, with adjustment for age, sex, nursing-home residence or nonresidence, smoking status, medical conditions, and receipt or nonreceipt of influenza vaccine. RESULTS: During the study period, 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagnosis of outpatient pneumonia, and 61 had pneumococcal bacteremia. Receipt of the pneumococcal vaccine was associated with a significant reduction in the risk of pneumococcal bacteremia (hazard ratio, 0.56; 95 percent confidence interval, 0.33 to 0.93) but a slightly increased risk of hospitalization for pneumonia (hazard ratio, 1.14; 95 percent confidence interval, 1.02 to 1.28). Pneumococcal vaccination did not alter the risk of outpatient pneumonia (hazard ratio, 1.04; 95 percent confidence interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required hospitalization (hazard ratio, 1.07; 95 percent confidence interval, 0.99 to 1.14). CONCLUSIONS: These findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention of bacteremia, but they suggest that alternative strategies are needed to prevent nonbacteremic pneumonia, which is a more common manifestation of pneumococcal infection in elderly persons.
引用
收藏
页码:1747 / 1755
页数:9
相关论文
共 50 条
  • [41] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [42] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Mikkelsen Malene B
    Husby Oyvind
    Molden Tor
    Mwaura David N
    Olsen Jens
    Kristensen Nanna V
    Vietri Jeffrey
    Cost Effectiveness and Resource Allocation, 21
  • [43] Recommendation for conjugate pneumococcal and pneumococcal polysaccharide vaccines in adults older than 65 years
    Niemi, Sarah A.
    Foster, Stephan L.
    Hayney, Mary S.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2015, 55 (02) : 212 - 215
  • [44] Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older
    Menzies, Robert I.
    Jayasinghe, Sanjay H.
    Krause, Vicki L.
    Chiu, Clayton K.
    McIntyre, Peter B.
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (02) : 112 - 115
  • [45] Vaccine Hesitancy Affecting Pneumococcal Vaccine Refusal in Older Adults with Morbidities
    Chitaree, Woothikrai
    Buawangpong, Nida
    Yotruangsri, Thanachat
    Jiraporncharoen, Wichuda
    Pinyopornpanish, Kanokporn
    JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2024, 15
  • [46] Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
    Kuo, Chia-Sheng
    Lu, Chia-Wen
    Chang, Yu-Kang
    Yang, Kuen-Cheh
    Hung, Shou-Hung
    Yang, Ming-Ching
    Chang, Hao-Hsiang
    Huang, Chi-Ting
    Hsu, Chih-Cheng
    Huang, Kuo-Chin
    MEDICINE, 2016, 95 (26)
  • [47] Pneumococcal polysaccharide vaccine uptake in England, 1989-2003, prior to the introduction of a vaccination programme for older adults
    Noakes, Karen
    Pebody, Richard G.
    Gungabissoon, Usha
    Stowe, Julia
    Miller, Elizabeth
    JOURNAL OF PUBLIC HEALTH, 2006, 28 (03) : 242 - 247
  • [48] PNEUMOCOCCAL POLYSACCHARIDE VACCINE UPDATE
    不详
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (7-8): : 676 - 676
  • [49] Pneumococcal polysaccharide vaccine in pregnancy
    Glezen, WP
    PEDIATRICS, 1999, 104 (06) : 1417 - 1418
  • [50] Pneumococcal polysaccharide conjugate vaccine
    不详
    AUSTRALIAN PRESCRIBER, 2010, 33 (02) : 56 - 57